Signal Ring, a new smart ring priced at $399, markets a method for tracking blood pressure directly from the finger. Both sources describe the ring’s main promise as providing systolic and diastolic readings without the need for a traditional upper-arm cuff or routine calibration. Digital Trends adds additional cautions, noting that the product does not appear to have FDA clearance and that published clinical evidence is not available in the reporting it cites. Android Authority similarly emphasizes the device’s goal of changing how consumers monitor blood pressure by delivering direct measurements. Taken together, the coverage highlights a contrast between the product’s technical claims—cuff-free readings and calibration-free use—and the availability of regulatory status and clinical validation. The reporting therefore indicates that consumers may still need to rely on conventional cuff-based devices, at least until clearance and clearer evidence are provided. No other specific performance metrics, study details, or timelines for approvals are presented in the provided excerpts.